Trevena Inc. is banking its future on possible approval of troubled pain medication Olinvo eight months after Phase III data raised some questions over the drug’s safety profile.

Spark Therapeutics Inc.’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.

Israeli medical device company Magenta Medical said it has raised $15 million in funding led by Massachusetts-based Abiomed Inc., a maker of catheter-based heart pumps, and venture capital firm Pitango.

New Novartis Chief Executive Officer Vasant Narasimhan has a goal of saving 25 percent of clinical trial costs by using digital technology.

Scientists often fail to publicly register plans for clinical trials or to publish the results, and the outcomes they do share may mask instances when new treatments are unsafe or ineffective, a small study suggests.

Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.

Carlsbad, Calif.-based Ionis Pharmaceuticals announced that GlaxoSmithKline declined its options on both inotersen and IONIS-FB-Lrx, which gives Ionis back control of those rights.

Feb. 12, 2018, is the day the U.S. FDA is expected to review Gilead Sciences’ HIV treatment that some analysts suggest could become a blockbuster.

Artificial intelligence robots are turbo-charging the race to find new drugs for the crippling nerve disorder ALS, or motor neurone disease.